MilliporeSigma
  • Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients.

Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients.

Diagnostics (Basel, Switzerland) (2021-04-04)
Nadine Ansorge, Christian Dannecker, Udo Jeschke, Elisa Schmoeckel, Doris Mayr, Helene H Heidegger, Aurelia Vattai, Maximiliane Burgmann, Bastian Czogalla, Sven Mahner, Sophie Fuerst
ABSTRACT

Vulvar cancer incidence numbers have been rising steadily over the past decades. Especially the number of young patients with vulvar cancer increased recently. Therefore, the need to identify new prognostic factors for vulvar carcinoma is more apparent. Cyclooxygenase-2 (COX-2) has long been an object of scientific interest in the context of carcinogenesis. This enzyme is involved in prostaglandin synthesis and the latter binds to nuclear receptors like PPARγ. Therefore, the aim of this study was to investigate COX-2- and PPARγ- expression in tissues of vulvar carcinomas and to analyze their relevance as prognostic factors. The cytoplasmatic expression of COX-2 as well as PPARγ is associated with a significantly reduced survival, whereas nuclear expression of PPARγ results in a better survival. Especially the combined expression of both COX-2 and PPARγ in the cytoplasm is an independent negative prognosticator for vulvar cancer patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-COX2 antibody produced in rabbit, affinity isolated antibody